Change in Liver Function in Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma

Nobuharu Tamaki; Nami Mori; Shintaro Takaki; KEIJI TSUJI; TOSHIFUMI TADA; Shinichiro Nakamura; Hironori Ochi; Toshie Mashiba; Masao Doisaki; Hiroyuki Marusawa; Haruhiko Kobashi; Hideki Fujii; Chikara Ogawa; Michiko Nonogi; HIROTAKA ARAI; Yasushi Uchida; Naohito Urawa; Ryoichi Narita; Takehiro Akahane; Masahiko Kondo; Yutaka Yasui; Kaoru Tsuchiya; Namiki Izumi; Masayuki Kurosaki

doi:10.21873/anticanres.17219

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Maintaining liver function throughout the treatment of hepatocellular carcinoma (HCC) is crucial, yet the impact of durvalumab plus tremelimumab (DT) treatment on liver function is not well understood. This multicenter study aimed to examine the changes in liver function during DT treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tamaki et al. (2024) studied this question.

synapsesocial.com/papers/68e5a81fb6db6435875428b9 https://doi.org/10.21873/anticanres.17219

View Full Paper

Ask AI

Bookmark

Share

Change in Liver Function in Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma

Ask about this paper

Abstract

Discussion

Cite This Study

Change in Liver Function in Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading